Alivus Life Sciences Ltd
NSE: GLS | BSE: 543322
₹1,031.40
₹-3.60
(-0.35%)
As on 10-Jun-2026IST
Market cap
₹12,643 Cr
Revenue (TTM)
₹2,552 Cr
P/E Ratio
22.4
P/B Ratio
3.8
Div. Yield
0.5 %
Quality Score
8/10
Growth Score
6/10
Valuation Score
5/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹564 Cr
-
ROE
18.9 %
-
ROCE
25.5 %
-
Industry P/E
45.87
-
EV/EBITDA
14.7
-
Debt to Equity
0
-
Book Value
₹271.5
-
EPS
₹47.6
-
Face value
2
-
Shares outstanding
122,739,448
8 Years Aggregate
CFO
₹2,301.62 Cr
EBITDA
₹3,925.38 Cr
Net Profit
₹2,702.04 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
| 12.5 | -8.0 | 12.1 | 1.6 | 20.4 | -- | -- |
|
BSE Healthcare
| 8.2 | 1.0 | 8.3 | 8.0 | 24.8 | 13.5 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Alivus Life Sciences
| -10.0 | 50.1 | 56.4 | -33.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
|
1,031.4 | 12,642.8 | 2,551.8 | 564.5 | 28.3 | 18.4 | 22.4 | 3.8 |
| 469.8 | 8,147.7 | 947.3 | 247.8 | 28.5 | 18.9 | 32.9 | 6.0 | |
| 1,330.7 | 13,881.0 | 1,054.9 | 256.3 | 27.8 | 13.7 | 53.2 | 6.9 | |
| 1,731.2 | 32,809.2 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.5 | 6.6 | |
| 384.1 | 4,199.5 | 165.8 | 46.7 | 37.8 | 16.9 | 90 | 14.6 | |
| 16,946.0 | 21,724.4 | 2,023.0 | 364.0 | 23.9 | 20.8 | 59.7 | 11.6 | |
| 851.0 | 4,312.9 | 811.3 | 21.0 | 0.7 | 2.1 | 209.9 | 3.3 | |
| 1,112.6 | 5,120.9 | 649.5 | 121.6 | 23.7 | 13.2 | 44.4 | 5.5 | |
| 731.4 | 8,265.6 | 502.0 | 138.7 | -- | 32.8 | 47.8 | 9.4 | |
| 268.8 | 7,086.2 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 12.0 |
Shareholding Pattern
View DetailsNews & Analysis
All News
IPO update: Glenmark Life Sciences
4 min read•By Danish Khanna
Glenmark Life Sciences IPO: Information analysis
6 min read•By Rajan Gulati and Arul Selvan
About Alivus Life Sciences
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan,... telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited. Read more
-
Incorporated
2011
-
Chairman
Hiren K Patel
-
Managing Director
Yasir Rawjee
-
Group
Glenmark
-
Headquarters
Solapur, Maharashtra
-
Website
Looking for more details about Alivus Life Sciences Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Alivus Life Sciences
What is the current share price of Alivus Life Sciences Ltd Today?
The share price of Alivus Life Sciences Ltd is ₹1,031.40 (NSE) and ₹1,030.05 (BSE) as of 10-Jun-2026 IST. Alivus Life Sciences Ltd has given a return of 20.43% in the last 3 years.
What is the current PB & PE ratio of Alivus Life Sciences Ltd?
The P/E ratio of Alivus Life Sciences Ltd is 22.40 times as on 10-Jun-2026, a 51 discount to its peers’ median range of 45.87 times.
The P/B ratio of Alivus Life Sciences Ltd is 3.79 times as on 10-Jun-2026, a 13 premium to its peers’ median range of 3.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
27.24
|
4.71
|
|
2024
|
20.17
|
4.09
|
|
2023
|
10.28
|
2.25
|
|
2022
|
13.43
|
2.74
|
|
2021
|
0.00
|
0.00
|
What is the 52 Week High and Low of Alivus Life Sciences Ltd?
The 52-week high and low of Alivus Life Sciences Ltd are Rs 1,148.40 and Rs 819.00 as of 11-Jun-2026.
What is the market cap of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd has a market capitalisation of ₹ 12,643 Cr as on 10-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Alivus Life Sciences Ltd?
Before investing in Alivus Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.